CBD for Pets in 2026: What the Latest Veterinary Research Actually Shows

The pet CBD market crossed $500 million in annual sales in the United States at the end of 2025, and it is projected to nearly double by 2028. Pet owners are buying CBD tinctures, chews, and topicals for their dogs and cats at an accelerating rate, driven by word-of-mouth testimonials and a growing body of veterinary research that — while still incomplete — is far more substantive than what existed even three years ago. The gap between consumer enthusiasm and scientific evidence is narrowing, but it has not closed.

This article examines what the peer-reviewed veterinary literature actually says about CBD for companion animals as of early 2026. We are going to cover the three conditions where evidence is strongest — osteoarthritis, anxiety, and seizure disorders — as well as what is known about dosing, safety, drug interactions, and the regulatory landscape that still leaves veterinarians in an awkward position.

The Pharmacology: How CBD Works in Dogs and Cats

Dogs and cats, like all mammals, possess an endocannabinoid system (ECS) consisting of CB1 and CB2 receptors distributed throughout the nervous system, immune tissue, and organ systems. The ECS modulates pain perception, inflammatory responses, mood, appetite, and immune function.

CBD (cannabidiol) does not bind strongly to CB1 or CB2 receptors in the way that THC does. Instead, it acts through indirect mechanisms — inhibiting the enzyme fatty acid amide hydrolase (FAAH), which breaks down the endogenous cannabinoid anandamide, and modulating serotonin receptors (5-HT1A), TRPV1 vanilloid receptors, and GPR55 orphan receptors. The net effect is a broad but subtle influence on pain signaling, inflammation, and neurological excitability.

One critical pharmacokinetic difference between species: dogs metabolize CBD much more slowly than humans, meaning the same mg/kg dose produces higher and more sustained blood levels. This has implications for both efficacy and side effects. Cats metabolize CBD differently again, with limited glucuronidation capacity that affects clearance rates. Species-specific dosing is not optional — it is essential.

Osteoarthritis: The Strongest Evidence

Canine osteoarthritis is where the veterinary CBD evidence is most robust. The landmark 2018 Cornell University study by Gamble et al. demonstrated that CBD oil at 2 mg/kg twice daily produced significant improvements in pain scores and activity levels in dogs with osteoarthritis, as assessed by both veterinarian evaluation and owner-reported measures. This was a randomized, placebo-controlled, double-blind study — the gold standard.

Since then, at least six additional controlled studies have been published examining CBD for canine joint pain, with broadly consistent results. A 2023 study from the University of Western Australia confirmed anti-inflammatory effects at the 2 mg/kg dose and identified reduced levels of pro-inflammatory cytokines in synovial fluid. A 2025 multi-center trial across four veterinary teaching hospitals found that dogs receiving CBD showed improvements in mobility scores comparable to those achieved with low-dose NSAIDs, though the study was not designed as a head-to-head comparison.

The evidence for cats with osteoarthritis is thinner but growing. A 2024 study published in the Journal of Feline Medicine and Surgery found that CBD at 2 mg/kg daily improved activity levels in cats with degenerative joint disease, though the sample size was small and the authors called for larger confirmatory trials.

For pet owners considering CBD for arthritis, the research supports cautious optimism. CBD is not a replacement for veterinary care or proven treatments, but it appears to offer genuine analgesic and anti-inflammatory benefits in dogs, with emerging evidence for cats. Our broader overview of CBD research for humans explores similar anti-inflammatory mechanisms.

Anxiety and Stress: Promising but Less Rigorous

Anxiety is the most common reason pet owners purchase CBD, but the clinical evidence is less developed than for arthritis. The most cited study is a 2020 trial by Hunt et al. that found CBD reduced aggressive behavior in shelter dogs, though the study design had limitations. A 2023 trial published in Frontiers in Veterinary Science examined CBD for noise-phobia in dogs during thunderstorms and fireworks, finding that treated dogs showed significantly lower cortisol levels and fewer stress behaviors than placebo controls.

A 2025 study from Colorado State University examined separation anxiety specifically — the most clinically relevant anxiety subtype for pet owners — and found that CBD at 4 mg/kg (higher than the arthritis dose) reduced destructive behavior and vocalization in dogs left alone, as measured by in-home video monitoring. However, the effect was moderate, and the researchers noted that CBD alone was less effective than behavioral modification combined with CBD.

For cats, anxiety research with CBD is minimal. A single small trial published in 2024 examined CBD for travel-related stress in cats and found modest reductions in stress markers, but the sample size was insufficient for firm conclusions.

The anxiety picture is complicated by the fact that many pet CBD products contain additional ingredients — chamomile, L-theanine, valerian root — making it difficult to attribute effects to CBD alone when owners report success. Veterinary behaviorists generally position CBD as a potential adjunct to behavior modification and environmental management, not a standalone solution.

Seizure Disorders: Significant Potential

Epilepsy treatment is where CBD first established credibility in human medicine, and veterinary research is following a similar trajectory. A 2019 Colorado State University study by McGrath et al. found that 89% of dogs receiving CBD experienced a reduction in seizure frequency, though the study had no placebo control. A follow-up placebo-controlled study in 2023 confirmed seizure reduction in dogs with idiopathic epilepsy receiving CBD as an add-on to conventional anticonvulsant medications.

The mechanism appears similar to what drives the human drug Epidiolex (pharmaceutical-grade CBD approved for certain epilepsy syndromes). CBD modulates neuronal excitability through multiple pathways, including TRPV1 receptor activation and GPR55 antagonism, reducing the likelihood of aberrant electrical discharges that trigger seizures.

Importantly, veterinary neurologists emphasize that CBD should not replace conventional anticonvulsants like phenobarbital or potassium bromide. The evidence supports CBD as an add-on therapy that may improve seizure control in dogs that are not fully responsive to standard medications. If you are interested in how cannabinoid research intersects with neurology more broadly, our cannabis and epilepsy coverage provides additional context.

Dosing: What the Research Supports

Dosing is where the gap between consumer products and veterinary science is most apparent. Most pet CBD products provide dosing instructions based on body weight, but the recommended doses vary wildly between brands.

The research-supported doses that have shown efficacy are:

For dogs with osteoarthritis: 2 mg/kg of body weight, given twice daily. For dogs with anxiety: 2 to 4 mg/kg, given once or twice daily depending on the situation (situational vs. chronic anxiety). For dogs with seizure disorders: 2.5 to 5 mg/kg, twice daily, as an add-on to existing anticonvulsant therapy. For cats: 2 mg/kg once daily for arthritis is the best-studied dose, though feline research is still limited.

These doses refer to actual CBD content, not total product volume. This is a critical distinction because CBD concentrations vary enormously between products. A 1-ounce bottle from one brand might contain 150 mg of total CBD, while another contains 1,500 mg. Reading the certificate of analysis (COA) from third-party lab testing is the only reliable way to verify what you are actually giving your pet.

Safety and Side Effects

The safety profile of CBD in dogs is generally favorable at studied doses. The most commonly reported side effects are mild sedation, gastrointestinal upset (soft stool or decreased appetite), and elevated alkaline phosphatase (ALP) liver enzyme levels. The ALP elevation has been consistently observed across multiple studies and warrants monitoring through periodic bloodwork, particularly in dogs receiving CBD long-term.

A 2024 hepatotoxicity study from the University of Florida found no evidence of clinically significant liver damage in healthy dogs receiving CBD at 5 mg/kg daily for 12 weeks, but dogs with pre-existing liver conditions may be more vulnerable. The researchers recommended baseline and follow-up liver panels for any dog starting CBD therapy.

Drug interactions are a legitimate concern. CBD inhibits cytochrome P450 enzymes in the liver — the same enzyme family responsible for metabolizing many pharmaceutical drugs. In dogs taking phenobarbital for seizures, CBD co-administration has been shown to increase phenobarbital blood levels, potentially pushing them into the toxic range. Similar interactions are plausible with other medications metabolized by the same pathways. Always consult with a veterinarian before adding CBD to a pet’s existing medication regimen.

THC toxicity is a separate and serious concern. Dogs are significantly more sensitive to THC than humans, and products containing more than trace amounts of THC can cause ataxia, urinary incontinence, disorientation, and in severe cases, prolonged sedation requiring veterinary intervention. Full-spectrum CBD products contain small amounts of THC (up to 0.3% by dry weight), which is generally well-tolerated, but products with higher THC content should never be given to pets.

The Regulatory Gap

Veterinarians in the United States remain in a difficult position regarding CBD. The FDA has not approved any CBD product for veterinary use, and in many states, veterinarians cannot legally prescribe or even formally recommend CBD. Some state veterinary boards have issued guidance permitting veterinarians to discuss CBD with clients, but the landscape is inconsistent.

The National Association of State Public Health Veterinarians has called for clearer federal guidance, and several veterinary professional organizations have formally supported reclassification efforts that would allow veterinarians to recommend CBD products with appropriate quality controls. The evolving regulatory landscape affects both human and veterinary applications.

Meanwhile, the pet CBD market remains largely self-regulated, with significant quality variation between products. A 2025 analysis of 50 commercially available pet CBD products found that only 64% contained CBD within 10% of the amount listed on the label. Some products contained detectable levels of heavy metals, pesticides, or residual solvents.

What to Look for in a Pet CBD Product

Based on the available evidence and veterinary guidance, pet owners should prioritize products that provide a current certificate of analysis from an ISO-accredited third-party laboratory, use CBD derived from hemp grown under regulated agricultural programs, contain less than 0.3% THC, clearly state the CBD concentration per milliliter or per unit dose, are formulated specifically for the target species (dog or cat, not human products repurposed for pets), and avoid proprietary blends that obscure the actual CBD content.

The pet CBD market in 2026 is large, growing, and unevenly regulated. The science is encouraging for specific conditions — particularly osteoarthritis and epilepsy in dogs — but it is not yet at the point where CBD should be considered a first-line treatment for anything in veterinary medicine. Pet owners who approach CBD as a carefully dosed, veterinary-supervised adjunct therapy rather than a cure-all are most likely to see genuine benefits for their animals. The broader trajectory of cannabis science suggests that veterinary applications will continue to expand as research funding and regulatory clarity improve in the years ahead.